-

Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will participate in the 44th J.P. Morgan Healthcare Conference 2026 taking place from January 12–15, 2026 in San Francisco. Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer’s Pharmaceuticals Division, will present updates on the company’s pharmaceutical growth strategy and pipeline advancements across its portfolio.

The presentation will take place on Tuesday, January 13, 2026, from 11:15 to 11:55 PST. Investors, analysts, media professionals and members of the life sciences industry are invited to join the live webcast of the presentation via this link. Following the event, the webcast will also be made available with materials related to the presentation on Bayer's website.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Find more information at https://pharma.bayer.com/
Follow us on Facebook: http://www.facebook.com/bayer
Follow us on X: @BayerPharma

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contacts

Media Contact:
Elaine Colón
Bayer Media Relations
elaine.colon@bayer.com
+1-732-236-1587

Bayer

GER:BAYN

Release Versions

Contacts

Media Contact:
Elaine Colón
Bayer Media Relations
elaine.colon@bayer.com
+1-732-236-1587

More News From Bayer

Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, in Combination With Antiplatelet Therapy Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved SUNHARBO® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicat...

Bayer and America’s Grow-a-Row Continue Partnership to Fight Food Insecurity

PITTSTOWN, N.J.--(BUSINESS WIRE)--In 2026, Bayer and America’s Grow-a-Row continued their longstanding partnership to combat food insecurity and expand access to fresh, nutritious produce for communities across the United States. Key Facts More than 200 Bayer employees volunteered with America’s Grow-a-Row on August 27 and October 1. Volunteers harvested 165,500 pounds of produce, equivalent to approximately 662,000 servings. Since 2020, Bayer Fund has provided more than $500,000 in grants to A...

Bayer to Present New Cardiovascular, Kidney and Stroke Data at the 2026 American Heart Association (AHA) Scientific Sessions

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that new data from its cardiovascular, kidney and stroke portfolios will be featured at the American Heart Association Scientific Sessions in Chicago, Illinois from November 6-9, 2026. Key Facts A late-breaking oral presentation will feature data from an exploratory post-hoc analysis of the Phase 3 OCEANIC-STROKE study, which evaluated asundexian versus placebo, both in combination with antiplatelet therapy, in patients after...
Back to Newsroom